Diabetes mellitus is a significant risk factor for the development of liver cirrhosis in chronic hepatitis C patients

Xu Li, Yang Gao, Hongqin Xu, Jie Hou & Pujun Gao

We explored the association between diabetes mellitus (DM) and the risk of hepatitis C virus (HCV)-related liver cirrhosis in Chinese patients with chronic hepatitis C (CHC). To examine the link between DM and liver cirrhosis, we conducted a case-control study of 210 Chinese CHC patients diagnosed with liver cirrhosis, comparing them to an age- and sex-matched control group of 431 CHC patients without liver cirrhosis. We conducted logistic regression analyses adjusting for demographic features and liver cirrhosis risk factors, and found that DM increased the risk of developing liver cirrhosis 2-fold (adjusted odds ratio (AOR), 2.132; 95% confidence interval (CI), 1.344–3.382). Furthermore, the proportion of liver cirrhosis patients and CHC-only patients with elevated serum triglycerides (>1.8 mmol/L) were 5.2% and 17.4%, respectively, yielding an AOR of 0.264 (95% CI, 0.135–0.517). Multivariate analyses that stratified the risk of developing HCV-related liver cirrhosis in DM patients by gender revealed that the estimated AOR (95% CI) for males was 0.415 (0.178–0.969). In conclusion, DM was associated with an increased risk of developing liver cirrhosis in CHC patients in China. Furthermore, among patients diagnosed with both CHC and DM, females had an increased risk of liver cirrhosis development.

Liver cirrhosis exemplifies end-stage chronic liver disease, and its prevalence is rising worldwide. In China, major known causes of liver cirrhosis include hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and excessive alcohol consumption. In particular, HCV infection is a significant health problem and differs from other hepatitis viruses in that it is a systemic disease, rather than just a liver disorder.

Recently, numerous extrahepatic manifestations of HCV infection have been reported; these include cardiovascular, central nervous system, renal, and metabolic diseases. Among the latter, diabetes mellitus (DM) is common in the general population. Studies that have assessed the association between DM or insulin resistance (IR) and HCV infection clearly demonstrate a significantly higher incidence of DM in patients with chronic HCV than in the general population, and show that HCV is significantly more common in patients with DM.

In our previous study, we demonstrated that DM increases hepatocellular carcinoma risk in treatment-naïve chronic hepatitis C (CHC) patients. Here, we conducted a case-control study in which we further investigated the association between DM, specific diabetes-related factors, and liver cirrhosis risk in CHC patients, controlling for other known liver cirrhosis risk factors.

Results

Patient demographics and clinical characteristics. Demographic and clinical data of the study participants are summarized in Table 1. We obtained complete diagnostic records for all 641 study participants, of which 431 had a diagnosis of CHC alone (CHC-only patients) and 210 were diagnosed with HCV-related liver cirrhosis (liver cirrhosis patients). The liver cirrhosis group was comprised of 39.5% males, with a median age of 59.00 (53.00, 66.25) years. The control group (CHC-only) was sex- and age-matched to the liver cirrhosis group.

1Department of Hepatology, The First Hospital of Jilin University, Jilin University, No. 71 Xinmin Street, Changchun, 130021, China. 2Jilin Province Key Laboratory of Infectious Disease, Laboratory of Molecular Virology, Changchun, 130021, China. 3Department of Neurology, The First Hospital of Jilin University, Jilin University, No. 71 Xinmin Street, Changchun, 130021, China. 4Department of Nephrology, The First Hospital of Jilin University, Jilin University, No. 71 Xinmin Street, Changchun, 130021, China. Correspondence and requests for materials should be addressed to P.G. (email: gpj0411@163.com)
Factors associated with liver cirrhosis development in CHC patients. Our univariate analyses suggested a higher incidence of gallstones and diabetes in patients who developed liver cirrhosis (Table 2). However, patients with CHC-only had higher levels of triglycerides (>0.8 mmol/L). In addition, sex, age, diabetes, hypertension, triglycerides, cholesterol, and gallstones were considered for multivariate analysis. After adjusting for potential confounding factors, the independent factors most strongly associated with liver cirrhosis were gallstones and DM. The associated risk of liver cirrhosis was two-fold higher in those with DM [AOR (95% CI), 2.132 (1.344–3.382); \( P = 0.001 \)], and two- to three-fold higher in those with gallstones [AOR (95% CI), 2.590 (1.701–3.946); \( P < 0.001 \)].

Interestingly, multivariate analysis also showed significantly different prevalence of hypertension and elevated triglycerides between the liver cirrhosis patients and the controls.

Association between diabetes duration, treatment, and complications, and the risk of developing liver cirrhosis. Because our studies identified diabetes as a major risk factor associated with liver cirrhosis, we further analyzed the association between liver cirrhosis risk and the following DM-related factors: the length of time over which the patient had DM, DM treatment method, whether or not the patient had DM complications (retinopathy, nephropathy, or neuropathy), and the presence of other health and lifestyle factors.

We also performed multivariate analyses examining the roles of sex, age, duration of DM, treatment for DM, DM retinopathy, DM nephropathy, DM neuropathy, triglycerides, cholesterol, and gallstones. Male CHC patients were at lower risk for liver cirrhosis development (AOR, 0.415; 95% CI, 0.178–0.969; \( P = 0.042 \)). Significant differences were observed in the prevalence of reduced triglyceride levels and gallstones between liver cirrhosis patients and the controls (\( P = 0.035; P = 0.008 \)). Conversely, our multivariate analyses did not indicate that the length of time over which CHC patients had diabetes affected the risk of liver cirrhosis development. Moreover, we found no correlation between the risk of developing liver cirrhosis and the DM treatment method or whether or not the patient had DM complications (retinopathy, nephropathy, or neuropathy).

### Table 1. Demographic and clinical characteristics of cases and controls.

Continuous variables are expressed as median (25th, 75th percentiles). Categorical variables are displayed as numbers and percentages.

| Variable                        | Liver cirrhosis N = 210 | CHC-only N = 431 | \( P \) |
|---------------------------------|-------------------------|-----------------|--------|
| Male, N (%)                     | 83 (39.5)               | 197 (45.7)      | 0.138  |
| Age (years)                     | 59.00 (53.00, 66.25)    | 57.00 (52.00, 63.00) | 0.208  |
| Diabetes, N (%)                 | 45 (21.4)               | 62 (14.4)       | 0.025  |
| Hypertension, N (%)             | 41 (19.5)               | 112 (26.0)      | 0.072  |
| Gallstones, N (%)               | 60 (28.6)               | 59 (13.7)       | <0.001 |
| AST (IU/L)                      | 60.00 (41.00, 92.73)    | 53.00 (31.00, 94.50) | 0.009  |
| ALT (IU/L)                      | 50.00 (30.00, 79.65)    | 67.00 (30.00, 132.00) | 0.002  |
| GGT (IU/L)                      | 47.05 (25.85, 85.40)    | 53.00 (25.00, 107.50) | 0.214  |
| ALP (IU/L)                      | 90.80 (70.98, 124.50)   | 82.00 (65.00, 108.00) | 0.002  |
| TBil (umol/L)                   | 27.40 (18.63, 48.55)    | 16.00 (11.50, 22.50) | <0.001 |
| ALB (g/L)                       | 31.00 (26.10, 35.73)    | 38.30 (35.30, 41.50) | <0.001 |
| CHE (IU/L)                      | 3378.50 (2267.50, 4978.00) | 7011.00 (5300.00, 8289.00) | <0.001 |
| Triglycerides (mmol/L)          | 0.86 (0.65, 1.13)       | 1.14 (0.86, 1.59) | <0.001 |
| Cholesterol (mmol/L)            | 3.48 (2.84, 4.10)       | 3.78 (3.28, 4.53) | <0.001 |
| Glucose (mmol/L)                | 5.27 (4.82, 6.32)       | 5.29 (4.85, 5.95) | 0.729  |
downstream antiviral effects of IFN to decrease both the rapid and sustained virological responses14, 15, 18. 

proteins and other precursors of hepatic fibrosis by hepatic stellate cells17. Insulin interferes with the intracellular 

lead to adverse outcomes in patients with chronic HCV. Furthermore, insulin stimulates the secretion of matrix 

the liver and its treatment. In addition, insulin is a growth factor and the high levels of insulin in patients with IR 

severe fibrosis. Similarly, a cohort study revealed that DM was an independent predictor of disease progression 

are associated with hepatic steatosis development13. Fibrosis progresses more rapidly to cirrhosis in patients with 

lipid export, impaired lipid degradation, and enhanced lipogenesis, which lead to hepatic steatosis and conse-

quent liver injury19, 20. Furthermore, IR, which is a common feature in DM, could also lead to the accumulation 

metabolism, which is disrupted by HCV core protein and the nonstructural protein 5A19. HCV causes impaired 

The reason for this might be as follows: firstly, we know that the HCV life cycle depends on host cell cholesterol 

in CHC patients11.

As we know, IR and DM negatively affect the liver in patients with chronic HCV12. These metabolic effects 

are associated with hepatic steatosis development13. Fibrosis progresses more rapidly to cirrhosis in patients with 

HCV, IR, and T2DM, except for HCV genotype 3, which is less responsive to treatment with interferon (IFN)14, 15. 

IR is independently associated with the progression of fibrosis16 and negatively influences the effects of HCV on 

the liver and its treatment. In addition, insulin is a growth factor and the high levels of insulin in patients with IR 

lead to adverse outcomes in patients with chronic HCV. Furthermore, insulin stimulates the secretion of matrix 

proteins and other precursors of hepatic fibrosis by hepatic stellate cells17. Insulin interferes with the intracellular 

downstream antiviral effects of IFN to decrease both the rapid and sustained virological responses14, 15, 18.

In this study, we found that females had a higher risk of liver cirrhosis in CHC patients who also had DM. The reason for this might be as follows: firstly, we know that the HCV life cycle depends on host cell cholesterol metabolism, which is disrupted by HCV core protein and the nonstructural protein 5A19. HCV causes impaired lipid export, impaired lipid degradation, and enhanced lipogenesis, which lead to hepatic steatosis and consequent liver injury18, 20. Furthermore, IR, which is a common feature in DM, could also lead to the accumulation of triglycerides by increasing the flux of free fatty acids into the liver21. We hypothesize that the above mentioned pathways by which HCV leads to liver injury might be enhanced when patients have concomitant DM, and the degree of enhancement differs in men and women. Secondly, DM is a risk factor for NASH, which can lead to liver fibrosis. Although the epidemiology of gender differences in NASH is somewhat controversial, data from cross-sectional studies22–32, which are based primarily on a histological diagnosis of nonalcoholic steatohepatitis (NASH), tend to suggest that the risk of NASH and advanced fibrosis is higher in females than males (independ-

ent of metabolic factors)32, 26–28, with only a few studies reporting conflicting results31, 29, 30.

Additionally, we found differences in triglyceride levels in CHC and liver cirrhosis patients. One possible explanation is that patients might change their dietary intake because of abdominal distension or other symptoms accompanying liver cirrhosis, which could reduce the serum levels of triglycerides. Furthermore, we found a higher prevalence of gallstones in patients with liver cirrhosis than in those with CHC alone, which is in line with the results of previous studies33–38. This may be attributed to the pathogenesis of gallstones in patients with chronic liver disease, which includes changes in the composition of hepatic bile, as well as gallbladder hypomotility38, 37. Gallbladder motility is decreased by increased levels of female sex steroid hormones, which usually occur with cirrhosis. Furthermore, liver cirrhosis patients have thicker gallbladder walls than chronic hepatitis-only patients, and these thicker walls may contribute to gallbladder hypomobility38–40.

Notably, we found no evidence that treatment for DM conferred an increased risk for the development of liver cirrhosis. The reasons might be as follows: first, drugs for DM treatment usually include metformin and insulin.

### Table 2

| Variable            | Liver cirrhosis N = 210 | CHC-only N = 431 | P*  | AOR (95% CI)* | P**  |
|---------------------|-------------------------|-----------------|-----|--------------|------|
| Sex                 |                         |                 | 0.138 | –            | –    |
| Female, N (%)       | 127 (60.5)              | 234 (54.3)      | –   | –            | –    |
| Male, N (%)         | 83 (39.5)               | 197 (45.7)      | –   | –            | –    |
| Age                 | 59.00 (53.00, 66.25)    | 57.00 (52.00, 63.00) | 0.208 | –            | –    |
| Diabetes            |                         |                 | 0.025 | 2.132 (1.344–3.382) | 0.001 |
| No, N (%)           | 165 (78.6)              | 369 (85.6)      | –   | –            | –    |
| Yes, N (%)          | 45 (21.4)               | 62 (14.4)       | –   | –            | –    |
| Hypertension        |                         |                 | 0.072 | 0.595 (0.387–0.915) | 0.018 |
| No, N (%)           | 169 (80.5)              | 319 (74.0)      | –   | –            | –    |
| Yes, N (%)          | 41 (19.5)               | 112 (26.0)      | –   | –            | –    |
| Triglycerides       |                         |                 | <0.001 | 0.264 (0.135–0.517) | <0.001 |
| ≤ 1.8 mmol/L, N (%) | 199 (94.8)              | 356 (82.6)      | –   | –            | –    |
| > 1.8 mmol/L, N (%) | 11 (5.2)                | 75 (17.4)       | –   | –            | –    |
| Cholesterol         |                         |                 | 0.577 | –            | –    |
| ≤ 6.0 mmol/L, N (%) | 204 (97.1)              | 415 (96.3)      | –   | –            | –    |
| > 6.0 mmol/L, N (%) | 6 (2.9)                 | 16 (2.9)        | –   | –            | –    |
| Gallstones          |                         |                 | <0.001 | 2.590 (1.701–3.946) | <0.001 |
| No, N (%)           | 150 (71.4)              | 372 (86.3)      | –   | –            | –    |
| Yes, N (%)          | 60 (28.6)               | 59 (13.7)       | –   | –            | –    |

*Adjusted for gender, age, hypertension, triglyceride, cholesterol, gallstones, and diabetes. **Adjusted for gender, age, hypertension, triglyceride, cholesterol, gallstones, and diabetes.

**Discussion**

In line with previous findings3, 9, our study demonstrated a two-fold higher prevalence of DM in cirrhosis patients, compared to a CHC-only control group that was age- and gender-matched. Likewise, Miyaki et al. compared the pathological and clinical characteristics of steatosis and metabolic syndrome in CHC patients, in order to identify risk factors for CHC with severe fibrosis90. They found that DM was significantly associated with severe fibrosis. Similarly, a cohort study revealed that DM was an independent predictor of disease progression in CHC patients11.

In this study, we found that females had a higher risk of liver cirrhosis in CHC patients who also had DM. This might be as follows: firstly, we know that the HCV life cycle depends on host cell cholesterol metabolism, which is disrupted by HCV core protein and the nonstructural protein 5A19. HCV causes impaired lipid export, impaired lipid degradation, and enhanced lipogenesis, which lead to hepatic steatosis and consequent liver injury18, 20. Furthermore, IR, which is a common feature in DM, could also lead to the accumulation of triglycerides by increasing the flux of free fatty acids into the liver21. We hypothesize that the above mentioned pathways by which HCV leads to liver injury might be enhanced when patients have concomitant DM, and the degree of enhancement differs in men and women. Secondly, DM is a risk factor for NASH, which can lead to liver fibrosis. Although the epidemiology of gender differences in NASH is somewhat controversial, data from cross-sectional studies22–32, which are based primarily on a histological diagnosis of nonalcoholic steatohepatitis (NASH), tend to suggest that the risk of NASH and advanced fibrosis is higher in females than males (independ-

ent of metabolic factors)32, 26–28, with only a few studies reporting conflicting results31, 29, 30.

Additionally, we found differences in triglyceride levels in CHC and liver cirrhosis patients. One possible explanation is that patients might change their dietary intake because of abdominal distension or other symptoms accompanying liver cirrhosis, which could reduce the serum levels of triglycerides. Furthermore, we found a higher prevalence of gallstones in patients with liver cirrhosis than in those with CHC alone, which is in line with the results of previous studies33–38. This may be attributed to the pathogenesis of gallstones in patients with chronic liver disease, which includes changes in the composition of hepatic bile, as well as gallbladder hypomotility38, 37. Gallbladder motility is decreased by increased levels of female sex steroid hormones, which usually occur with cirrhosis. Furthermore, liver cirrhosis patients have thicker gallbladder walls than chronic hepatitis-only patients, and these thicker walls may contribute to gallbladder hypomobility38–40.

Notably, we found no evidence that treatment for DM conferred an increased risk for the development of liver cirrhosis. The reasons might be as follows: first, drugs for DM treatment usually include metformin and insulin.

---

**Table 2.** Univariate and multivariate analyses of variables associated with hepatitis C virus-related liver cirrhosis. CHC = chronic hepatitis C; AOR = adjusted odds ratio; CI = confidence interval. *P value for univariate analysis. *Adjusted for gender, age, hypertension, triglyceride, cholesterol, gallstones, and diabetes. **Adjusted for gender, age, hypertension, triglyceride, cholesterol, gallstones, and diabetes.
Metformin could reduce the levels of circulating insulin and aid in improving responses to antiviral treatment, including a combination of pegylated IFN alpha-2a (PEG-IFN \( \alpha \)-2a) and ribavirin (RBV), in patients with CHC of the naïve genotype 1 (G1) subtype. Therefore, metformin might decrease the incidence of liver cirrhosis in patients with CHC. However, external insulin could increase the levels of circulating insulin and aggravate liver fibrosis, as discussed above. Therefore, hypoglycemic drugs might have different effects on liver cirrhosis development in different CHC patients, resulting in the lack of an observable impact of DM treatment on liver cirrhosis development in this study.

The principal limitations of this study are its retrospective design, and the lack of details regarding the type of oral hypoglycemic agents used for treatment. Further study is needed to understand the association between hypoglycemic agents and liver cirrhosis development. Secondly, the number of cases in our study was not large, leading to a small number of subjects in the subgroup analyses. The case numbers were limited by our desire to exclude patients without blood lipid and glucose data. Therefore, our insignificant findings with respect to diabetes duration, treatment, and complications may be a reflection of these low numbers.

In conclusion, we found that DM increased the risk of liver cirrhosis development among CHC patients in China. Our findings also suggested that, for patients dually diagnosed with CHC and DM, female patients may experience an enhanced risk of developing liver cirrhosis.

### Methods

**Patient selection.** This was a cross-sectional study to investigate risk factors associated with liver cirrhosis in CHC patients who were hospitalized at The First Hospital of Jilin University in China from January 2011 to December 2016. All methods were carried out in accordance with the approved guidelines. In total, 641 patients with CHC infection, as diagnosed by the presence of HCV RNA and anti-HCV antibodies in the serum for ≥6
months, were recruited for inclusion in our study. Of these, 210 patients had liver cirrhosis. After matching for sex and age in the cases group, 431 patients constituted the control sample group.

Subjects were excluded for the following criteria: (i) co-infection with HBV or human immunodeficiency virus; (ii) history or evidence of any type of cancer; (iii) history or evidence of infection with other hepatitis types; or (iv) presence of other liver disease, such as nonalcoholic fatty liver disease (NAFLD) or alcoholic liver disease.

The Independent Institutional Review Board of The First Hospital of Jilin University approved the study protocol and the recruitment of human subjects. We obtained written informed consent from each patient upon enrollment in the study.

**Diagnosis of liver cirrhosis.** Liver cirrhosis was diagnosed either by liver biopsy, or based on combined clinical findings, biochemistry, and radiology.

**Diagnosis of DM.** DM was diagnosed in patients with known history of DM under anti-diabetic therapy or at least one of the following criteria: (1) fasting glucose level ≥7.0 mmol/L; (2) random glucose level ≥11.1 mmol/L; or (3) 2-h post-load plasma glucose ≥11.1 mmol/L.

**Study variables.** We analyzed the following demographic, lifestyle, and health-related variables in this study: sex, age, hypertension, gallstones, presence of DM, duration of DM, treatment of DM, and complications of DM (such as diabetic retinopathy, nephropathy, or neuropathy). Furthermore, we examined the following biochemical parameters: alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), albumin (ALB), cholinesterase (CHE), gamma-glutamyl transferase (GGT), triglycerides, cholesterol, and glucose.

**Statistical analysis.** Continuous variables are presented as the median (25th, 75th percentiles), and categorical variables are displayed as numbers and percentages. To determine the significance of our findings, we employed a chi-square test for categorical variables. For normally distributed continuous variables, we employed an independent sample t-test. All tests were two-tailed. We employed multivariate logistic regression to adjust for possible confounding effects among the variables. Additionally, adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated for these comparisons. Statistical analyses were performed using SPSS version 13.0 software (SPSS Inc., Chicago, IL, USA). P-values < 0.05 were considered to represent statistical significance.

**References**

1. Kanwal, F. et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. *Gastroenterology* 140, 1182–1188.e1181, doi:10.1053/j.gastro.2010.12.032 (2011).
2. Wiegand, J. & Berg, T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. *Deutsches Arzteblatt international* 110, 85–91, doi:10.3238/arztebl.2013.0085 (2013).
3. Desbois, A. C. & Cacoub, P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. *World journal of gastroenterology* 23, 1697–1711, doi:10.3748/wjg.v23.i9.1697 (2017).
4. Cacoub, P., Gragnani, L., Comarmond, C. & Zignego, A. L. Extrapathic manifestations of chronic hepatitis C virus infection. *Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver* 46(Suppl 3), S165–173, doi:10.1016/j.dld.2014.01.005 (2014).
5. Mehta, S. H. et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. *Annals of internal medicine* 133, 592–599 (2000).
6. Mehta, S. H. et al. Hepatitis C virus infection and incident type 2 diabetes. *Hepatology (Baltimore, Md.)* 38, 50–56, doi:10.1053/ jhep.2003.50291 (2003).
7. Wang, C. S., Wang, S. T., Yao, W. J., Chang, T. T. & Chou, P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. *American journal of epidemiology* 166, 196–203, doi:10.1093/aje/kwm061 (2007).
8. Li, X. et al. Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naive chronic hepatitis C patients in China. *Medicine (Baltimore, Md.)* 96, e6508, doi:10.1097/md.0000000000006508 (2017).
9. Raff, E. J. et al. Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-Alcoholic Fatty Liver Diseases. *Journal of clinical and translational hepatology* 3, 9–16, doi:10.14218/jch.2015.00001 (2015).
10. Miyakawa, H. et al. Predictive value of the fibrosis scores in patients with chronic hepatitis C associated with liver fibrosis and metabolic syndrome. *Internal medicine (Tokyo, Japan)* 50, 1137–1141 (2011).
11. Allafé, E. Z. et al. The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy. *Liver international: official journal of the International Association for the Study of the Liver* 33, 871–883, doi:10.1111/liv.12127 (2013).
12. Shiffman, M. L. & Gunn, N. T. Impact of hepatitis C virus therapy on metabolism and public health. *Liver international: official journal of the International Association for the Study of the Liver* 37(Suppl 1), 13–18, doi:10.1111/liv.13282 (2017).
13. Bakuš, I. G. et al. [Diabetes mellitus and nonalcoholic fatty liver disease: The verges of contingency?]. *Terapevticheskii arkhiv* 89, 59–65, doi:10.17116/terapevthia2017892596-65 (2017).
14. Kumar, D., Farrell, G. C., Fung, C. & George, J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatocyte steatosis after sustained therapeutic response. *Hepatology (Baltimore, Md.)* 36, 1266–1272, doi:10.1053/jhep.2002.36370 (2002).
15. Poynard, T. et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology (Baltimore, Md.)* 38, 75–85, doi:10.1053/jhep.2003.36267 (2003).
16. Hui, J. M. et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. *Gastroenterology* 125, 1695–1704 (2003).
17. Paradis, V. et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. *Hepatology (Baltimore, Md.)* 34, 738–744, doi:10.1053/ jhep.2001.20535 (2001).
18. Dai, C. Y. et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. *Journal of hepatology* 50, 712–718, doi:10.1016/j.jhep.2008.12.017 (2009).
19. Chang, M. L. Metabolic alterations and hepatitis C: From bench to bedside. *World journal of gastroenterology* 22, 1461–1467, doi:10.3748/wjg.v22.i14.1461 (2016).
20. Syed, G. H., Amako, Y. & Siddiqui, A. Hepatitis C virus hijacks host lipid metabolism. *Trends in endocrinology and metabolism: TEM* 21, 33–40, doi:10.1016/j.tem.2009.07.005 (2010).
21. Kosmidou, M. & Milionis, H. Diabetes mellitus and non-alcoholic fatty liver disease: the thread of Ariadne. Minerva endocrinologica 42, 109–121, doi:10.23736/s0391-1977.162562-1 (2017).
22. Singh, D. K., Sakhuja, P., Malhotra, V., Gondal, R. & Sarin, S. K. Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis. Digestive diseases and sciences 53, 1967–1976, doi:10.1007/s10620-007-0074-0 (2008).
23. Fossain, N. et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 7, 1224–1229, 1229.e1221–1222, doi:10.1016/j.cgh.2009.06.007 (2009).
24. Younossi, Z. M. et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 91, 319–327, doi:10.1097/MD0b013e3182779d49 (2012).
25. Al-hamoudi, W. et al. Epidemiological, clinical, and biochemical characteristics of Saudi patients with nonalcoholic fatty liver disease: a hospital-based study. Annals of Saudi medicine 32, 288–292, doi:10.5144/0256-9477.2012.288 (2012).
26. Bambah, K. et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.) 55, 769–780, doi:10.1002/hep.24276 (2012).
27. Wang, Z., Xu, M., Hu, Z., Huls trom, M. & Lai, E. Sex-specific prevalence of fatty liver disease and associated metabolic factors in Wuhan, south central China. European journal of gastroenterology & hepatology 26, 1015–1021, doi:10.1097/meg.0000000000000151 (2014).
28. Tapper, E. B. et al. Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterology report 2, 276–280, doi:10.1093/gastro/gou034 (2014).
29. Yang, J. D. et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.) 59, 1406–1414, doi:10.1002/hep.26761 (2014).
30. Turola, E. et al. Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. Disease models & mechanisms 8, 1037–1046, doi:10.1242/dmm.019950 (2015).
31. Klar, J. S. et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.) 64, 85–91, doi:10.1002/hep.28514 (2016).
32. Yang, J. D. et al. Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 15, 127–131.e122, doi:10.1016/j.cgh.2016.07.034 (2017).
33. Li, X., Wang, Z., Wang, L., Pan, M. & Gao, P. Liver cirrhosis: a risk factor for gallstone disease in chronic hepatitis C patients in China. Medicine 99, e7427, doi:10.1097/md.0000000000007407 (2020).
34. Acalovschi, M. Gallstones in patients with liver cirrhosis: incidence, etiology, clinical and therapeutic aspects. World journal of gastroenterology 20, 7277–7285, doi:10.3748/wjg.v20.i23.7277 (2014).
35. Stroffolini, T., Sagnelli, E., Mele, A., Cotton, C. & Almasio, P. L. HCV infection is a risk factor for gallstone disease in liver cirrhosis: an Italian epidemiological survey. Journal of viral hepatitis 14, 618–623, doi:10.1111/j.1365-2893.2007.00845.x (2007).
36. Park, J. H., Kim, T. N. & Lee, S. H. The prevalence and risk factors of gallstones in Korean patients with liver cirrhosis. Hepatogastroenterology 60, 461–465, doi:10.5754/hge11950 (2013).
37. Sherlock, S. & Dooley, J. S. Diseases of the Liver and Biliary System. Eleventh edition edn, (Blackwell Science Ltd a Blackwell Publishing Company, 2002).
38. Fried, G. M. et al. Comparison of cholecystokinin release and gallbladder emptying in men and in women at estrogen and progesterone phases of the menstrual cycle. Surgery 95, 284–289 (1984).
39. For nari, E. et al. Cirrhosis of the liver. A risk factor for development of cholelithiasis in males. Digestive diseases and sciences 35, 1403–1408 (1990).
40. Buzas, C., Chira, O., Mocan, T. & Acalovschi, M. Comparative study of gallbladder motility in patients with chronic HCV hepatitis and with HCV cirrhosis. Romanian journal of internal medicine = Revue roumaine de medecine interne 49, 37–44 (2011).
41. Donadon, V., Balbi, M., Mas, M. D., Casarini, P. & Zanette, G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver international: official journal of the International Association for the Study of the Liver 30, 750–758, doi:10.1111/j.1478-3231.2010.02223.a (2010).
42. Chang, C. H. et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology (Baltimore, Md.) 55, 1462–1472, doi:10.1002/hep.25509 (2012).
43. Chen, H. P. et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62, 606–615, doi:10.1136/gut-2011-301708 (2013).
44. Zhou, Y. et al. Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma. Scientific reports 6, 33743, doi:10.1038/srep33743 (2016).
45. Romero-Gomez, M. et al. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology (Baltimore, Md.) 50, 1702–1708, doi:10.1002/hep.23206 (2009).
46. Alberti, K. G. & Zimmet, P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes medicine: a journal of the British Diabetic Association 15, 539–553, doi:10.1002/diab.1998015175 <3539-aai-dia6683.3.0.co2-s (1998).

Author Contributions
Xu Li: Study concept and design, drafting of the manuscript. Yang Gao: Acquisition of data and administrative, technical, and material support. Hongjin Xu: Analysis and interpretation of data. Jie Hou: Statistical analysis. Pujuan Gao: Study supervision and critical revision of the manuscript for important intellectual content.

Additional Information
Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017